荃信生物-B 02509Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name荃信生物-B
Stock Code02509
Company Full Name荃信生物-B
Industry醫療保健
Principal Activities公司是中國一家完全專注于針對自身免疫及過敏性疾病生物療法的臨床階段生物科技公司,擁有自主研發的藥物管線及完善的商業級規模內部生產能力。
Listing Date2024-03-20
Listing Rules EraOld Rules
Listing Rules ChapterNo data
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省泰州市藥城大道907號1號樓1310室
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttp://www.qyuns.net/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo data
// Offering Information //
Offering Mechanism 未知
Clawback TiersNo data
Prospectus Date2024-03-12
Offer PriceHK$ 19.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Par ValueNo data
Global Offering Shares12,046,400
HK Public Offering Shares— (0.0%)
International Placing Shares— (0.0%)
Offer RatioNo data
Total Shares Post-IPONo data
Total Global Offering SizeHK$ —
Public Offering SizeHK$ — (0.0%)
Oversubscription Multiple163.2x
Valid Applications14,525
Accepted Applications4,237
ReallocationNo
Total Funds RaisedHK$ 42,387,840
Greenshoe (Over-allotment Option)No data
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
Pre-IPO Valuation (Last Round)No data
P/E Ratio-13.22
Profit/Loss StatusNo data
Period-End Cash BalanceNo data
Listing Expenses~HK$ 75,250,000
Listing Expenses / Funds RaisedNo data
Total Pre-IPO InvestmentNo data
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 27.4
First Day Change23.74%
First Day Volume2308200.0
First Day Turnover61672700.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約30.1%或49.2百萬港元將分配至核心產品QX002N的開發及注冊; 2、約54.6%或89.3百萬港元將分配至其他核心產品QX005N的開發及注冊; 3、約8.7%或14.2百萬港元將分配至QX004N的開發及注冊; 4、約1.9%或3.1百萬港元將分配至QX006N的臨床試驗、QX006N準備注冊文件以及CMC成本; 5、約4.7%或7.7百萬港元將分配至若干其他資產的研發和藥物發現。
// Underwriting Syndicate //
独家保荐人 (1)
中国国际金融香港证券有限公司
整体协调人 (3)
中国国际金融香港证券有限公司 安信国际证券(香港)有限公司 国泰君安证券(香港)有限公司
联席账簿管理人 (7)
中国国际金融香港证券有限公司 安信国际证券(香港)有限公司 国泰君安证券(香港)有限公司 华泰金融控股(香港)有限公司 兴证国际融资有限公司 利弗莫尔证券有限公司 老虎证券(香港)环球有限公司
联席牵头经办人 (12)
中国国际金融香港证券有限公司 安信国际证券(香港)有限公司 国泰君安证券(香港)有限公司 华泰金融控股(香港)有限公司 兴证国际融资有限公司 利弗莫尔证券有限公司 老虎证券(香港)环球有限公司 复星国际证券有限公司 巨诚证券有限公司 浦银国际融资有限公司 中国银河国际证券(香港)有限公司 洪泰证券有限公司
// Cornerstone Investors // Allotment Results Announcement
#Investor NameShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 有限公司 5,930,400 49.23% 2.90%
// Directors & Management //
Chairman裘霽宛
Company Secretary胡衍保
No director data available.
// Major Shareholders //
Major Shareholders & Holdings杭州荃毅投資管理合伙企業(普通合伙)(18.01%);杭州中美華東制藥有限公司(16.17%);泰州洪泰健康投資管理中心(有限合伙)(8.44%);泰州信孚同心企業管理合伙企業(有限合伙)(7%)
// Allotment Benchmarks //
Pool A (Small Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
200 4,099 205 0.05
Pool B (Large Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
400 2,128 192 0.09
600 481 58 0.12
800 277 39 0.14
1,000 467 73 0.16
1,200 141 24 0.17
1,400 110 21 0.19
1,600 107 22 0.21
1,800 74 16 0.22
2,000 2,289 527 0.23
3,000 313 99 0.32
4,000 757 269 0.36
5,000 244 101 0.41
6,000 200 93 0.47
7,000 98 51 0.52
8,000 123 69 0.56
9,000 106 64 0.60
10,000 364 236 0.65
12,000 139 102 0.73
14,000 93 75 0.81
16,000 93 82 0.88
18,000 74 71 0.96
20,000 468 468 1.00
30,000 221 72 1.32
40,000 156 94 1.60
50,000 170 145 1.85
60,000 98 98 2.01
70,000 57 18 2.31
80,000 52 27 2.52
90,000 30 22 2.75
100,000 108 99 2.90
120,000 23 23 3.00
140,000 19 7 3.36
160,000 35 27 3.76
180,000 21 21 3.96
200,000 77 24 4.30
300,000 135 124 20.85
400,000 23 23 26.00
500,000 10 10 31.00
602,400 45 45 36.14
Allotment Benchmarks
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics